A Retrospective Chart Review Evaluating Efficacy, Tolerability, and Cost of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors (PCSK9i) in Older Adults
ConclusionsPCSK9i are effective at lowering LDL-C in older adults. Tolerability was high among patients without a history of statin intolerance. PCSK9i remain high-cost medications to both insurance companies and patients in terms of cost-sharing responsibilities.
Source: High Blood Pressure and Cardiovascular Prevention - Category: Cardiology Source Type: research
More News: Cardiology | Cardiovascular | Cholesterol | Heart | Hypertension | Insurance | Insurers | Statin Therapy | Study | USA Health